426 related articles for article (PubMed ID: 26099606)
21. Kallikrein-related peptidase 6 (KLK6) expression in the progression of colon adenoma to carcinoma.
Vakrakou A; Devetzi M; Papachristopoulou G; Malachias A; Scorilas A; Xynopoulos D; Talieri M
Biol Chem; 2014 Sep; 395(9):1105-17. PubMed ID: 25153391
[TBL] [Abstract][Full Text] [Related]
22. TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome.
Aleskandarany MA; Negm OH; Rakha EA; Ahmed MA; Nolan CC; Ball GR; Caldas C; Green AR; Tighe PJ; Ellis IO
Breast Cancer Res Treat; 2012 Nov; 136(2):419-27. PubMed ID: 23053644
[TBL] [Abstract][Full Text] [Related]
23. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
24. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer.
Petraki C; Dubinski W; Scorilas A; Saleh C; Pasic MD; Komborozos V; Khalil B; Gabril MY; Streutker C; Diamandis EP; Yousef GM
Pathol Res Pract; 2012 Feb; 208(2):104-8. PubMed ID: 22285222
[TBL] [Abstract][Full Text] [Related]
25. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of NDRG3 in patients with breast cancer.
Estiar MA; Zare AA; Esmaeili R; Farahmand L; Fazilaty H; Jafari D; Samadi T; Majidzadeh-A K
Future Oncol; 2017 May; 13(11):961-969. PubMed ID: 28326836
[TBL] [Abstract][Full Text] [Related]
27. Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis.
Tokas T; Avgeris M; Alamanis C; Scorilas A; Stravodimos KG; Constantinides CA
J Cancer Res Clin Oncol; 2017 Mar; 143(3):521-532. PubMed ID: 27858162
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer.
Kyriakopoulou LG; Yousef GM; Scorilas A; Katsaros D; Massobrio M; Fracchioli S; Diamandis EP
Clin Biochem; 2003 Mar; 36(2):135-43. PubMed ID: 12633763
[TBL] [Abstract][Full Text] [Related]
31. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D
Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797
[TBL] [Abstract][Full Text] [Related]
32. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
[TBL] [Abstract][Full Text] [Related]
33. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
35. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
[TBL] [Abstract][Full Text] [Related]
36. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
Heikkinen T; Korpela T; Fagerholm R; Khan S; Aittomäki K; Heikkilä P; Blomqvist C; Carpén O; Nevanlinna H
Breast Cancer Res Treat; 2013 Aug; 141(1):79-88. PubMed ID: 23974830
[TBL] [Abstract][Full Text] [Related]
37. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.
Zheng M; Zhou Y; Yang X; Tang J; Wei D; Zhang Y; Jiang JL; Chen ZN; Zhu P
Breast Cancer Res Treat; 2014 Nov; 148(2):423-36. PubMed ID: 25348432
[TBL] [Abstract][Full Text] [Related]
38. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
Park YH; Jung HH; Do IG; Cho EY; Sohn I; Jung SH; Kil WH; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH
Int J Cancer; 2015 Apr; 136(8):1976-84. PubMed ID: 25537444
[TBL] [Abstract][Full Text] [Related]
39. The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression.
Michaelidou K; Tzovaras A; Missitzis I; Ardavanis A; Scorilas A
Int J Oncol; 2013 May; 42(5):1770-7. PubMed ID: 23525470
[TBL] [Abstract][Full Text] [Related]
40. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
